Navigation Links
Icagen Terminates Phase III ASSERT Study

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Apr 3, 2007 - Icagen, Inc. (NASDAQ: ICGN) announced today that following a planned meeting of the independent Data Monitoring Committee ("DMC") of the Company's ASSERT trial of senicapoc (formerly ICA-17043) for the treatment of sickle cell disease in adults, the DMC recommended that the trial be terminated because of the low probability of achieving a reduction in crisis rate, the primary endpoint. In making their recommendation, the DMC noted that data from the trial indicated the expected increases in hemoglobin and hematocrit and decreases in reticulocytes as well as LDH and bilirubin, both markers of hemolysis. Among the available data, there were no statistically significant differences in safety measurements between the senicapoc and placebo treatment groups. The Company has informed the FDA of its plan to terminate the study based upon the DMC's recommendation. The Company will analyze final data when available and consider future options for the development of senicapoc.

About Icagen

Icagen, Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. Utilizing its proprietary know-how and integrated scientific and drug development capabilities, Icagen has identified multiple drug candidates that modulate ion channels. The Company's four most advanced programs are: -0-

 - senicapoc for sickle cell disease, which is discussed above.

    Senicapoc is being co-developed under an agreement with the McNeil

    Pediatrics Division of McNeil-PPC, Inc., a subsidiary of Johnson &

    Johnson.

-0-
 - lead compounds for epilepsy and neuropathic pain, for which the

    Company is conducting preclinical studies;

-0-
- a lead compound for atrial fibril
'"/>




Page: 1 2 3

Related medicine technology :

1. Icagen to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Icagen Terminates Phase III ASSERT Study
(Date:2/26/2015)... , Feb. 26, 2015  IRIDEX Corporation (NASDAQ: ... quarter and full year 2014 financial results after the market ... with the release, the Company will host a conference call ... on Thursday, March 5, 2015 to discuss ... Interested parties may access the live conference call via ...
(Date:2/26/2015)... -- Legislation passed today by the House Ways and ... inappropriate prescriptions in Medicare Part D from crossing the ... Act (PIMA) of 2014 , introduced by Ways and ... and Ranking Member Jim McDermott (D-WA), recognizes the need ... the right policies, said the Pharmaceutical Care Management Association ...
(Date:2/26/2015)... , Feb. 26, 2015 Research and Markets ... the "Radiation Therapy Equipment - Global Strategic Business ... This report analyzes the worldwide markets for Radiation Therapy ... Linear Accelerator, Treatment Planning Systems, and Radiation Therapy Simulator. ... Canada , Japan ...
Breaking Medicine Technology:IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2PCMA Statement on the 'Protecting the Integrity of Medicare Act' 2Radiation Therapy Equipment - Global Strategic Business Report 2015-2020: Linear Accelerator, Treatment Planning Systems, and Radiation Therapy Simulator 2
... Lead to More Effective Antibiotics Against ,Superbugs, ... College of Engineering may have discovered the path,toward ... that have developed resistance to common antibiotics. The,researchers ... occurring,in bacteria that opens to door to new ...
... Clinical ... WHIPPANY, N.J. and ATLANTA, Sept. 6 ... terms to acquire Zurich,Biostatistics, Inc. (ZBI). With the ... acquisition further strengthens,ISI,s Clinical Data Interchange Standards Consortium ...
Cached Medicine Technology:Boston University Biomedical Engineers Find Chink in Bacteria's Armor 2Boston University Biomedical Engineers Find Chink in Bacteria's Armor 3Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 2Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 3
(Date:2/27/2015)... Beverly Hills, CA (PRWEB) February 27, 2015 ... Health found a correlation between men who cycle on ... for your overall health, the study suggests that the more ... he is to develop prostate cancer, leading to an increased ... important because it allows physicians to look more closely at ...
(Date:2/27/2015)... February 27, 2015 Those ... are often misunderstood, misdiagnosed and therefore aren’t ... healthy lives. Jacksonville-based addiction treatment center ... its highly acclaimed Lakeview Professional Lecture Series ... in understanding this complicated condition. ...
(Date:2/27/2015)... 2015 On March 2-4, the ... National Cancer Institute (NCI) will co-host the annual ... Institutes of Health (NIH), in Bethesda, Maryland. The ... to medical professionals and scientists who specialize in ... general public, including patients, their families, and caregivers. ...
(Date:2/27/2015)... 27, 2015 Altec Products, Inc., announced ... been chosen as their doc-link for Dynamics Partner of ... other complimentary solutions for their customers in all different ... unions. Altec and BPW have worked side-by-side to successfully ... Dynamics GP. , “We are so impressed by the ...
(Date:2/27/2015)... Diego, CA (PRWEB) February 27, 2015 ... Vortex-Genie® 2 , price is only valid until ... to lab technicians looking for a vortex mixer that ... Scientific Industries was founded in 1954 and is headquartered ... laboratory mixers & shakers, as well as other rockers, ...
Breaking Medicine News(10 mins):Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3Health News:Lakeview Health to Host Important Workshop Tackling the Rising Issue of ‘Cutters’ on March 27 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 3Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 3Health News:Pipette.com Announces Limited Time Offer of 24% Off List Price on the Vortex-Genie 2 2
... birth defects, research shows , THURSDAY, Oct. 1 (HealthDay ... give birth to babies with heart defects, a new study ... researchers analyzed data on 6,440 infants with congenital heart defects ... in the National Birth Defects Prevention Study. , Women who ...
... Urges Congress to Pass Relief Legislation for Older Americans - ... Oct. 1 In the midst of dwindling retirement savings ... more bad news that could spell disaster for many - ... Today, AARP announced it will urge Congress to immediately ...
... drugs urged for moms-to-be , THURSDAY, Oct. 1 (HealthDay News) ... from H1N1 swine flu as of the end of August, ... federal health officials said Thursday. , While the officials said ... the number of deaths from the H1N1 flu could be ...
... (WSNA), representing more than 16,000 registered nurses in Washington State, ... System for unilaterally implementing a mandatory vaccination policy. This new ... to wear face masks as a condition of employment and ... comply with the policy. The lawsuit seeks an injunction to ...
... and cardiologists across the country are reaching out to ... preserved as discussions about healthcare reform continue. ... Medicaid Services (CMS) - scheduled to become law January ... life-saving cardiology testing and services currently available in cardiology ...
... System study has found that high-risk surgery patients ... seen by general internists trained in managing medical ... high-risk orthopaedic surgeries experienced shorter stays when their ... And, the study found, patients reported they were ...
Cached Medicine News:Health News:Pre-Pregnancy Weight Linked to Babies' Heart Problems 2Health News:28 Pregnant Women Have Died From Swine Flu: CDC 2Health News:28 Pregnant Women Have Died From Swine Flu: CDC 3Health News:Washington State Nurses Association Seeks Injunction in Federal Court to Block Mandatory Vaccination Policy by MultiCare Health System 2Health News:Proposed Medicare Changes Will Increase Costs to Government, Decrease Options for Patients 2Health News:Proposed Medicare Changes Will Increase Costs to Government, Decrease Options for Patients 3Health News:How to reduce hospital stays and increase patient satisfaction 2
Round handle McPherson angled tying forceps with 10 mm tips and 5 mm titanium coated platforms. Length 110 mm....
This standard tying forcep is curved with 5mm titanium coated platforms. Length 85 mm....
Catalano angled tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Kelman - McPherson angled tying forceps is long with tying platform 10 mm, serrated handle and polished finish....
Medicine Products: